Networks, Cities, and Data: The Future of Better H...

If you’re not convinced the future of healthcare has arrived, just wait a few days:  it should be coming to a mobile device or a big box store near you soon: Quantified-self software by which you can monitor every bodily function and have the data integrated into your medical record. Low-cost Genomic profiling to identify your disease risks. Biomarker-directed personalized drugs that are optimally efficacious for your particular molecular sub-group of disease. Self-help health maintenance tools to integrate all that bodily function monitoring and your genomics profile with the right drugs and food/exercise choices to slow or prevent...

The Prognosis for Participatory Care

As “The Innovator’s Partner,” we embrace new ideas and the big impact they can have in addressing disease and improving health. We are passionately enthusiastic about the role we and our clients can play in enhancing each patient’s journey, care, and outcomes. But what do health care providers—in whose hands the fate of many of these new tools and treatments rest—think about all this innovation? Do they get as excited as we do? For some, the answer appears to be, “Not so much.” Significant numbers of docs are in fact reluctant to embrace new diagnostic methods and tools, slow to adopt electronic health...

Personalized, More or Less

We live in an increasingly impersonal world. We hide behind technology. We text instead of talking – sometimes when we’re in the same room. We shop online. We “share” virtually. Yet — and, to some degree, as a result — we also live in a world where information about us is more widely available than ever, creating the ability to hyper-personalize communication and track our every move (as the Ed Snowden revelations remind us). So what does this emerging tension—the impersonal nature of technology-driven interchange vs. the personalization enabled by the vast array of data trailing behind such...

Here’s to the Next 25

Feinstein Kean Healthcare has spent the past 25 years laboring productively in the vineyards of disruptive innovation. The firm was born in the cradle of biotech and worked with many of the industry’s pioneers. We were there in the early days of stem cell research, oncogenes and immunotherapies, nanotech, many of the “omics” and, more recently, big data, cognitive gaming and the digitization of medicine. We’ve helped to open up entirely new categories of treatment in many disease areas, and changed the mindset in others. We were the first in the communications industry to anticipate the impact of personalized medicine—and (thanks...